Dimensional Fund Advisors LP Has $5.88 Million Stake in SI-BONE, Inc. (NASDAQ:SIBN)

Dimensional Fund Advisors LP cut its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 31.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 454,975 shares of the company’s stock after selling 209,531 shares during the quarter. Dimensional Fund Advisors LP owned about 1.10% of SI-BONE worth $5,882,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SIBN. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in SI-BONE by 24.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after acquiring an additional 2,108 shares during the last quarter. Arizona State Retirement System grew its stake in SI-BONE by 9.0% during the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after purchasing an additional 903 shares during the period. Assenagon Asset Management S.A. acquired a new stake in SI-BONE during the second quarter worth approximately $152,000. RiverPark Advisors LLC increased its holdings in SI-BONE by 260.4% in the first quarter. RiverPark Advisors LLC now owns 11,357 shares of the company’s stock worth $186,000 after purchasing an additional 8,206 shares in the last quarter. Finally, EntryPoint Capital LLC lifted its stake in SI-BONE by 78.4% in the first quarter. EntryPoint Capital LLC now owns 13,906 shares of the company’s stock valued at $228,000 after buying an additional 6,113 shares during the period. Institutional investors own 98.11% of the company’s stock.

Insider Buying and Selling

In other SI-BONE news, CFO Anshul Maheshwari sold 2,418 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $13.87, for a total transaction of $33,537.66. Following the transaction, the chief financial officer now directly owns 198,762 shares in the company, valued at approximately $2,756,828.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other SI-BONE news, CFO Anshul Maheshwari sold 2,418 shares of SI-BONE stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $13.87, for a total transaction of $33,537.66. Following the transaction, the chief financial officer now owns 198,762 shares of the company’s stock, valued at $2,756,828.94. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,905 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $13.84, for a total value of $54,045.20. Following the completion of the transaction, the insider now owns 238,804 shares in the company, valued at $3,305,047.36. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,019 shares of company stock worth $349,879. 5.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

SIBN has been the subject of several recent analyst reports. Needham & Company LLC reduced their price objective on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Morgan Stanley reduced their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Truist Financial dropped their price objective on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.00.

SI-BONE Stock Up 1.6 %

SI-BONE stock opened at $13.45 on Wednesday. The firm has a market capitalization of $554.21 million, a price-to-earnings ratio of -12.34 and a beta of 1.22. The firm’s fifty day moving average price is $14.88 and its two-hundred day moving average price is $14.65. SI-BONE, Inc. has a 1-year low of $11.76 and a 1-year high of $22.56. The company has a current ratio of 9.17, a quick ratio of 8.12 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.04. The business had revenue of $39.97 million for the quarter, compared to analysts’ expectations of $38.95 million. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. During the same quarter last year, the firm earned ($0.30) EPS. On average, equities research analysts predict that SI-BONE, Inc. will post -0.89 earnings per share for the current fiscal year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.